ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,127.79
      1.26%
      US Tech 100
      17,446.00
      2.17%
      Dow Jones
      38,675.68
      1.18%
      Brent Oil
      82.765
      0.00%
      Bitcoin
      63,792.97
      -0.16%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Alterity Therapeutics Limited (ATHE)

      7. Alterity Therapeutics Limited (ATHE) News

      ATHE

      Alterity Therapeutics (ATHE)

      Alterity Therapeutics Limited
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:ATHE
      DateTimeSourceHeadlineSymbolCompany
      04/30/20247:25AMGlobeNewswire Inc.Appendix 4C – Q3 FY24 Quarterly Cash Flow ReportNASDAQ:ATHEAlterity Therapeutics Limited
      04/29/20247:25AMGlobeNewswire Inc.Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s AtaxiaNASDAQ:ATHEAlterity Therapeutics Limited
      04/17/20247:25AMGlobeNewswire Inc.Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual MeetingNASDAQ:ATHEAlterity Therapeutics Limited
      04/10/20247:25AMGlobeNewswire Inc.Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024NASDAQ:ATHEAlterity Therapeutics Limited
      03/26/202410:25AMGlobeNewswire Inc.Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive RefundNASDAQ:ATHEAlterity Therapeutics Limited
      02/20/202410:25AMGlobeNewswire Inc.Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual MeetingNASDAQ:ATHEAlterity Therapeutics Limited
      02/15/20245:29PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
      02/15/20245:28PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ATHEAlterity Therapeutics Limited
      02/06/20247:25AMGlobeNewswire Inc.Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second ReviewNASDAQ:ATHEAlterity Therapeutics Limited
      01/31/20248:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
      01/29/20247:24AMGlobeNewswire Inc.Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This WeekNASDAQ:ATHEAlterity Therapeutics Limited
      01/22/20247:25AMGlobeNewswire Inc.Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming MilestonesNASDAQ:ATHEAlterity Therapeutics Limited
      01/22/20246:12AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
      01/18/20248:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
      01/11/20245:19PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
      01/11/20245:16PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
      01/10/20246:03AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
      01/08/20248:03AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
      01/08/20248:02AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
      01/08/20248:01AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
      01/08/20248:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
      01/05/20246:27AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
      01/05/20246:24AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
      01/02/20248:04AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
      01/02/20248:02AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
      01/02/20248:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
      12/29/20238:02AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
      12/29/20238:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
      12/21/20238:02AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
      12/21/20238:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
       Showing the most relevant articles for your search:NASDAQ:ATHE